Can Cell Therapy Be Prepared On-Site and On-Demand? The Truth Revealed

For companies currently positioning themselves in the cell and gene therapy (CGT) sector, strengthening quality management across the entire product lifecycle, exploring investment and financing opportunities, enhancing innovation capabilities, implementing efficient international expansion strategies, and maintaining operational viability have become core strategic issues that innovative pharmaceutical enterprises must urgently address amid the ongoing capital winter. Meanwhile, in the field of cell and gene therapy, technological innovation should not only focus on the advancement of the technology itself but also prioritize its real-world clinical effectiveness and patient experience.

With the rapid advancement of cell therapy technologies, the traditional centralized manufacturing model can no longer fully meet the demands of personalized treatment. There remains substantial market demand for more precise, efficient, and safer therapeutic approaches. Key challenges urgently requiring exploration in the CGT industry include overcoming traditional spatial and temporal constraints, shortening patient treatment cycles, seizing critical therapeutic windows, and alleviating the financial burden of treatment on patients.

At the same time, we also observe that Point-of-Care Manufacturing (POCM), as a disruptive innovation model, is leveragingRevolutionizing Efficiency, Practicing Inclusive Healthcare, and Safeguarding Quality Throughout the Care Continuumand other advantages are reshaping the industry landscape.